Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it has entered into a definitive agreement with a newly established portfolio company of Syncona Ltd (LON: SYNC), a leading life science investor focused on creating, building and scaling global leaders in life...

  The Danish drug maker plans to pay up to $2.7bn to Flagship Pioneering-incubated Valo Health for its AI-enabled small molecule discovery and human genetic data platform. Novo Nordisk gets a license to three preclinical-stage cardiovascular disease programmes from Valo Health...

  Sandoz, a global leader in generic and biosimilar medicines, announced that it has entered into a development and commercialization agreement with Samsung Bioepis. The agreement provides Sandoz with the exclusive rights to commercialize the biosimilar SB17 ustekinumab in the...

  Sandoz, a global leader in generic and biosimilar medicines, announced that the European Commission (EC) granted marketing authorization for the first and only biosimilar Tyruko® (natalizumab), developed by Polpharma Biologics. The European approval for Tyruko comes a month...

  Italian company Alfasigma has signed a definitive agreement for the acquisition of all issued and outstanding shares in Intercept Pharmaceuticals. Alfasigma will pay $19 for each share of Intercept. The acquisition will help boost Alfasigma’s gastroenterology and hepatology...

  Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Mindset Pharma, Inc. (Mindset) announce that they have entered into a definitive arrangement agreement pursuant to which Otsuka will acquire Mindset for approximately CAD 80 million in an all-cash transaction. The Otsuka and Mindset...

  Global science and technology provider Danaher has signed a definitive agreement for the acquisition of all outstanding stakes in UK-based protein consumables supplier Abcam in a deal valued at $5.7bn. Under the terms of the agreement, Danaher will acquire all the outstanding...

    Scientific instruments maker Bruker has agreed to buy PhenomeX for about $108 million, marking its entry into the market for functional single-cell biology research systems. PhenomeX supplies an analysis platform that enables researchers to characterize tens of...

  Revolution Medicines, Inc.  a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, and EQRx, Inc. today announced a definitive agreement through which Revolution Medicines plans to acquire EQRx in an all-stock transaction intended to add more...

  BioNTech has officially completed the acquisition of InstaDeep Ltd.—a technology company in the artificial intelligence (AI) and machine learning (ML) space— for approximately $549 million.  The takeover follows a collaboration between the two parties since 2019 and an equity...